Clinical Trial Update: Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab plus amurubicin in patients with refractory small cell lung cancer (extensive stage).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer Extensive Stage

Drugs mentioned

• Amurubicin (amurubicin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Wakayama Medical University | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 2 | Status: UNKNOWN